227 related articles for article (PubMed ID: 28717217)
1. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.
Ogura H; Nagatake-Kobayashi Y; Adachi J; Tomonaga T; Fujita N; Katayama R
Sci Rep; 2017 Jul; 7(1):5519. PubMed ID: 28717217
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
3. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
4. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
6. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract][Full Text] [Related]
8. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Drilon A; Somwar R; Wagner JP; Vellore NA; Eide CA; Zabriskie MS; Arcila ME; Hechtman JF; Wang L; Smith RS; Kris MG; Riely GJ; Druker BJ; O'Hare T; Ladanyi M; Davare MA
Clin Cancer Res; 2016 May; 22(10):2351-8. PubMed ID: 26673800
[TBL] [Abstract][Full Text] [Related]
9. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
10. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
12. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
[TBL] [Abstract][Full Text] [Related]
13. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
14. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
16. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
[TBL] [Abstract][Full Text] [Related]
17. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
[TBL] [Abstract][Full Text] [Related]
18. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
[TBL] [Abstract][Full Text] [Related]
19. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
[TBL] [Abstract][Full Text] [Related]
20. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]